Integra LifeSciences (IART) announced enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the AERA Eustachian Tube Balloon Dilation System in children.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra Lifesciences Amends Credit Agreement for Stability
- Integra Lifesciences Approves Equity Plan Amendment
- Integra LifeSciences price target lowered to $25 from $35 at Citizens JMP
- Integra LifeSciences price target lowered to $15 from $19 at Truist
- Integra LifeSciences price target lowered to $13 from $25 at Wells Fargo